Promising GSK-3β inhibitors are already widely investigated for bipolar disorder [8,9], AD [10], inflammatory diseases [11], Acquired Immune Deficency Syndrome (AIDS) [12], diabetes [13,14] and cancer [15]. The gene discussed is GSK3B; the disease is bipolar disorder.